Gliclagood 80 Tablet contains Gliclazide 80 mg, an oral hypoglycemic agent belonging to the sulfonylurea class, primarily indicated for the management of type 2 diabetes mellitus. It functions by stimulating insulin secretion from the pancreatic beta cells, thereby improving glycemic control in patients with non-insulin-dependent diabetes. Gliclazide enhances insulin release in response to meals, contributing to the reduction of both fasting and postprandial blood glucose levels. This medication is typically prescribed when diet, exercise, and weight reduction alone have not achieved adequate glycemic control. Gliclagood 80 Tablet should be administered once daily with breakfast to optimize efficacy and minimize the risk of hypoglycemia. Dose adjustments may be necessary based on individual patient response and glycemic targets. Caution is advised in patients with renal or hepatic impairment, and it is contraindicated in individuals with type 1 diabetes, diabetic ketoacidosis, or hypersensitivity to sulfonylureas. Common adverse effects include hypoglycemia, gastrointestinal disturbances, and allergic skin reactions. Regular monitoring of blood glucose levels and periodic assessment of renal and hepatic function are recommended during therapy. Gliclagood 80 Tablet should be used under medical supervision as part of a comprehensive diabetes management plan.